lifestyle.californiaconsumerbanking.com

Author: Tevogen Bio Inc

Letter to Shareholders from CEO Dr. Ryan Saadi

May 18, 2026
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

May 12, 2026
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

May 7, 2026
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

May 4, 2026
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 4, 2026
Tevogen Names Leadership Team to Execute Diversified Growth Strategy

May 3, 2026
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

May 2, 2026
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

May 2, 2026
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

May 2, 2026
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

May 1, 2026